Small Breast Mass Found in 34-Year-Old Woman

Poll

A 34-year-old woman presents with a small tumor mass in the right breast. After a biopsy is obtained, what is your diagnosis?

A 34-year-old woman presents with a small tumor mass in the right breast. According to the pathology slide image below, what is your diagnosis?

What is your diagnosis?

A. Ductal carcinoma
B. Granular cell tumor
C. Lobular carcinoma
D. Malignant lymphoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
2 experts in this video
2 experts in this video
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content
71 Beyond the Surface: Suspicious Nipple Lesions

71 Beyond the Surface: Suspicious Nipple Lesions

Margarita Riojas Barrett;Logan Healy;Neil Farnsworth;Elizabeth Bonefas;Alastair Thompson;Stacey Carter
May 8th 2025
Article
Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Roman Fabbricatore
May 8th 2025
Article

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
May 1st 2025
Podcast

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.

Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer

Roman Fabbricatore
May 8th 2025
Article

Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.

"Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option," according to the study authors.

Concurrent Chemoradiation May Improve LS-SCLC Prognosis

Russ Conroy
May 8th 2025
Article

Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.